exRNAdisease

General Information

Database ID:

exR0084222

RNA Name:

VCP

RNA Type:

mRNA

Chromosome:

chr9

Starnd:

Coordinate:

Start Site(bp):

35056064

End Site(bp):

35072627

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AACS	chr12	125065434	125143333	+
ABHD12	chr20	25294742	25390835	-
AC005258.1	chr19	2269525	2341172	+
AC010422.3	chr19	12643831	12648397	-
AC073896.1	chr12	56285916	56316059	-
AC091167.2	chr15	90249556	90272208	+
AC093525.2	chr16	2496032	2520218	+
ACADS	chr12	120725774	120740008	+
ACBD6	chr1	180269653	180502954	-
ACTG1	chr17	81509971	81523847	-
ADAR	chr1	154582057	154628013	-
ADH5	chr4	99070978	99088801	-
AL121753.1	chr20	35267885	35280043	-
ALDH2	chr12	111766887	111817532	+
ALDH7A1	chr5	126531200	126595362	-

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-331-3p	chr12	95308480	95308500	+
hsa-miR-339-5p	chr7	1022990	1023012	-
hsa-miR-520a-5p	chr19	53690895	53690915	+
hsa-miR-450b-5p	chrX	134540231	134540252	-

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC002310.1	chr16	30534752	30537149	+
AC112484.1	chr3	128860620	128871540	-
AC132217.1	chr11	2129121	2129964	-
AC245014.3	chr1	145281116	145281462	+
AD000090.1	chr19	35557956	35581954	+
AL031282.2	chr1	1702736	1737688	-
AL121992.1	chr1	15586136	15603626	-
AL135925.1	chr10	79825902	79827602	+
AL136985.3	chr1	58715609	58771295	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference